VISKA BIO
VISKA Bio is an early-stage immunotherapy platform that engages localized immunogenic cell death to treat and prevent cancer. The company is based in Cambridge, Massachusetts.
VISKA BIO
Social Links:
Industry:
Biotechnology Medical
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.viska.bio
Total Employee:
1+
Status:
Active
Technology used in webpage:
Euro Squarespace Hosted
Similar Organizations
Abacus Bioscience
Abacus Bioscience specializes in developing immunotherapies for treating chronic infectious diseases and cancers.
Adze Biotechnology
Adze Biotechnology is a pre-clinical stage company that develops oncolytic immunotherapies for the treatment of cancers.
BlueSphere Bio
BlueSphere Bio is a novel TCXpress technology to unlock the potential of personalized T-cell therapy for the treatment of cancer .
ESCAPE Bio
ESCAPE Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
GlyTR Therapeutics
GlyTR Therapeutics develops a novel immunotherapy platform technology targeting diverse cancer types, from breast cancer to leukemia.
OncoMyx Therapeutics
OncoMyx Therapeutics develops oncolytic immunotherapies to assist in creating an immune response and treat cancer.
Teiko.bio
Teiko.bio is an immune profiling platform that enables clinicians to make informed decisions around patient response.
Thiogenesis Therapeutics
Thiogenesis Therapeutics is a clinical-stage biotech company that develops thiol-active therapeutics to treat medical diseases.
Thrive Earlier Detection
Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Current Employees Featured
Founder
Official Site Inspections
http://www.viska.bio
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "VISKA Bio"
Viska.Bio
Contact Us. LabCentral. 700 Main Street. Cambridge, MA 02139See details»
VISKA Bio - Crunchbase Company Profile & Funding
Organization. VISKA Bio . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. VISKA Bio is an early-stage immunotherapy platform that …See details»
Viska.Bio 2025 Company Profile: Valuation, Funding
When was Viska.Bio founded? Viska.Bio was founded in 2021. Where is Viska.Bio headquartered? Viska.Bio is headquartered in Cambridge, MA. …See details»
VISKA Bio - LinkedIn
VISKA Bio | 524 followers on LinkedIn. Engaging localized immunogenic cell death in cancer therapy | Located in LabCentral, the premier shared lab facility for life science startups in the …See details»
About Viska Bio - labcentral-site.files.svdcdn.com
About Viska Bio Viska Bio focuses on treating chronic and infectious diseases by harnessing the body's innate immune response. Using patented fusion proteins, our technology naturally …See details»
VISKA - Company Profile - Tracxn
Mar 4, 2025 VISKA - Developer of immunotherapy for cancer treatment. Raised funding from 1 investor. Founded by Eric Fossel and Victor Reinoso in the year 2021. VISKA has 508 …See details»
VISKA.BIO - VentureRadar
At VISKA.BIO, we propose a unique way to target cancer through the body's innate immune system. Our innovative fusion protein will act to kill circulating cancer cells and prevent …See details»
VISKA Bio Overview | SignalHire Company Profile
Organization Website: viska.bio : VISKA Bio industries Biotech: Headquarters Location: LabCentral, 700 Main Street, Cambridge, Massachusetts, 02139 US LabCentral, 700 Main …See details»
VISKA Bio - Crunchbase
VISKA Bio is an early-stage immunotherapy platform that engages localized immunogenic cell death to treat and prevent cancer. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
VISKA Bio - Drug pipelines, Patents, Clinical trials - Synapse
Last update 19 Sep 2024. VISKA Bio. Private Company |See details»
Approach - Viska.Bio
The VISKA Approach. At VISKA.BIO, we propose a unique way to target cancer through the body's innate immune system. Our innovative fusion protein will act to kill circulating cancer cells and prevent recurrence of cancer.See details»
Viska.Bio - Products, Competitors, Financials, Employees, …
Viska.Bio focuses on leveraging immunogenic cell death for cancer therapy within the biotechnology sector. Use the CB Insights Platform to explore Viska.Bio's full profile. Viska.Bio …See details»
Team - Viska.Bio
Contact Us. LabCentral. 700 Main Street. Cambridge, MA 02139See details»
VISKA Bio - Contacts, Employees, Board Members, Advisors
VISKA Bio is an early-stage immunotherapy platform that engages localized immunogenic cell death to treat and prevent cancer. ... Experience the new Crunchbase, powered by AI . …See details»
Associate through Principal Associate - Biology - LabCentral
Viska Bio is an innovative, early-stage company that is developing a unique immune-oncology modality for the treatment of different cancers. Viska Bio is currently looking for experienced …See details»
Viska.Bio - CB Insights
Explore {Viska.Bio's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
General 2 — Viska.Bio
Viska’s technology utilizes a fusion protein with targeted delivery to EGFR-expressing cancer cells. Our primary indication is Glioblastoma with a direct path to IND-enabling studies in late …See details»
Chalk Talk: VISKA.BIO - LabCentral | Cambridge, MA
Jun 20, 2023 Location: 700 Main Lobby Date: June 20 Time: 12PM - 1PM We are back with another Chalk Talk with Vsika.Bio. They are proposing a unique way to target…See details»
GSK’s Kim Branson on driving innovation with AI and machine …
Mar 4, 2025 In this episode of Eureka!, a McKinsey podcast on innovation in life sciences R&D, hosts Navraj Nagra and Alex Devereson speak to Kim Branson, senior vice president and …See details»
Side-Stepping the Guardian of the Genome: Current Cancer …
Oct 1, 2024 VISKA.Bio Inc. Author Profile. Abstract. Cancer therapies have attempted to target the transcription factor p53, a gene also described as the “guardian of the genome,” for …See details»